Gemcitabina nel mesotelioma peritoneale: Presentazione di un caso clinico

Clinica Terapeutica

Volumn 149, Issue 6, 1998, Pages 447-451

  Amodio, A ^a,b   Crecco, M ^a   Del Medico, P ^a   Paoletti, G ^a   Lopez, M ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b II Div Med   (Italy)

Author keywords

CA 125; Gemcitabine; Peritoneal mesothelioma

Indexed keywords

CA 125 ANTIGEN; GEMCITABINE;

ADULT; ARTICLE; ASCITES; CASE REPORT; DRUG EFFICACY; FEMALE; HUMAN; MALIGNANT MESOTHELIOMA; PERITONEUM MESOTHELIOMA;

ANTIMETABOLITES, ANTINEOPLASTIC; CA-125 ANTIGEN; DEOXYCYTIDINE; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MESOTHELIOMA; MIDDLE AGED; PERITONEAL NEOPLASMS; TIME FACTORS;

EID: 0032462836     PISSN: 00099074     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Hrarup-Hansen A, Hansen HH: Chemotherapy in malignant mesothelioma: A review. Cancer Chemother Pharmacol 28:319-330, 1991
2. Mintzer DM, Kelsen D, Frimmer D, et al.: Phase II trial of high dose cisplatin in patients with malignant mesothelioma. Cancer Treat Rep 69: 711-712, 1985
3. Zidar BL, Green S, Pierce HI, et al.: A phase II evaluation of cisplatin in unresectable diffuse malignant mesothelioma: a Southwest Oncology Group study. Invest New Drugs 6: 223-226, 1988
4. Planting AST, Schellens JHM, Goey SH, et al: Weekly high-dose cisplatin in malignant pleural mesothelioma. Ann Oncol 5: 373-374, 1994
5. Ong ST, Vogelzang NJ: Chemotherapy in malignant pleural mesothelioma: a review. J Clin Oncol 14(3):1007-1017, 1996
6. Van Meerbeeck JP, Baas P, Debruyne C, et al: Gemcitabine in malignant pleural mesothelioma: A phase II study. Lung Cancer 18(S1):17, 1998 (abstr 57)
7. Bishoff HG, Manegold C, Knopp M, et al: Gemcitabine may reduce tumor load and tumor associated symptoms in malignant pleural mesothelioma. Proc Am Soc Clin Oncol 17: 464a, 1998 (abstr 1784)
8. Byrne MJ, Davidson JA, Musk AW, et al.: Cisplatin and gemcitabine treatment for malignant mesothelioma: A phase II study. Proc Am Soc Clin Oncol 17:464a, 1998 (abstr 1783)
9. Huang P, Chubb S, Hertel LW, et al: Action of 2',2'-difluorodeoxycytidine on DNA synthesis. Cancer Res 51: 6110-6117, 1991
10. Peters GJ, Bergman AM, Ruiz van Haperen VWT, et al.: Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin Oncol 22(S11):72-79, 1995
11. Bateman ac, AL-Talib RK, Newman T, et al.: Immunohistochemical phenotype of malignant mesothelioma: predictive value of CA125 and HBME-1 expression. Histopathology 30(1): 49-56
12. Simsek H, Hadayifci A, Okan E: Importance of serum CA 125 levels in malignant peritoneal mesothelioma. Tumour Biol 17(1):1-4, 1996